Allakos Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Allakos Contact Number

Allakos, 975 Island Drive, Redwood City, CA

2 hours ago Allakos.com Show details

(650) 597-5002

Allakos Inc. is located at 975 Island Drive, Suite 201, Redwood City, CA 94065. email [email protected]allakos.com or call (650) 597-5002

1. 975 Island Dr Ste 201, Redwood City, CA 94065 · (650) 597-5002DIRECTIONSWEBSITE

Category: Contact NumberShow more

Allakos AK002 mAb Eosinophilic Gastroenteritis

4 hours ago Allakos.com Show details

Allakos AK002 mAb Eosinophilic Gastroenteritis. Developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. Lirentelimab (AK002) An investigational monoclonal antibody selectively targeting Siglec-8, an inhibitory receptor found on mast cells and eosinophils. Eosinophilic Gastrointestinal Diseases (EGIDs

Category: Contact NumberShow more

Allakos Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

Contact Email [email protected]allakos.com Phone Number (650)597-5002 Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells.

Founded: 2012
Founder: Christopher Bebbington

Category: Contact NumberShow more

Clinical AK002 Eosinophilic Gastritis Allakos

3 hours ago Allakos.com Show details

Allakos has initiated a registrational Phase 3 study in patients with eosinophilic gastritis and/or eosinophilic duodenitis (see EG/EoD study brochure). Eosinophilic Esophagitis (EoE) Eosinophilic esophagitis (EoE) is a condition characterized by mast cell …

Category: Contact NumberShow more

Robert Alexander phone & email Allakos Inc Chief

7 hours ago Easyleadz.com Show details

Robert Alexander - Chief Executive Officer - Allakos Inc - email id & phone of top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head.

Occupation: Vice President
Works For: Allakos.Com
Work Location: menlo park, california

Category: Phone NumberShow more

Allakos Inc Biocom California

2 hours ago Biocom.org Show details

About Allakos Inc. Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on

Category: Contact NumberShow more

Allakos Allakos

3 hours ago Divedeeper.com Show details

Please input your 10-digit NPI number * I authorize Allakos to analyze and use my information to improve or develop services and programs and to contact me regarding website updates and for marketing purposes regarding Allakos products, services, market research, clinical trials, and/or other information related to eosinophilic disease

Category: Contact NumberShow more

Allakos Inc Email Format allakos.com Emails

4 hours ago Rocketreach.co Show details

Allakos Inc Email Format. Allakos Inc uses 2 email formats, with first_initial last (ex. [email protected]allakos.com) being used 99.0% of the time. Get Verified Emails for Allakos Inc Employees. Allakos Inc's Email Format. Percentage.

Category: Contact NumberShow more

ALLAKOS (NASDAQ: ALLK)

Just Now Organize.worksmartsuite.com Show details

22 23-33

about speaking to Allakos -the co-founder plus what we infer to be contact with the CMO -which if true would strike us as reckless and raise concerns about trial tampering and Allakos’ conduct in general. Pages 8-22 23-33 34-46 47-55 56-61 62-77 4

Category: Contact NumberShow more

Allakos Company Profile Office Locations, Competitors

4 hours ago Craft.co Show details

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update Content Import Mon, 05/10/2021 - 16:02 Allakos Reports First Quarter 2021 Financial Results and Provides Business Update May 10, 2021 at 4:01 PM EDT This release is a backfill fr…

Category: Contact NumberShow more

Allakos Medical Information

7 hours ago Allakosddw2021.com Show details

Allakos is a clinical-stage biotechnology company developing therapeutic antibodies for allergic, inflammatory, and proliferative diseases. Our lead drug candidate is an investigational monoclonal antibody designed to target Siglec-8, an inhibitory receptor selectively found …

Category: Contact NumberShow more

Allakos Therapeutic antibodies Eosinophils and Mast cells

9 hours ago Allakos.com Show details

Our lead drug candidate is lirentelimab (AK002), an investigational antibody that targets Siglec-8, an inhibitory receptor selectively found on mast cells and eosinophils. In clinical and preclinical studies, lirentelimab has been shown to broadly inhibit mast cells and rapidly deplete eosinophils.

Category: Cell PhoneShow more

Open Positions at Allakos

7 hours ago Allakos.com Show details

An Equal Opportunity Employer, Allakos values and encourages diversity in the workplace Clinical Operations. Associate Director / Senior Manager, Clinical Development Program Manager. Commercial. Director of Patient Marketing. Director, Market Access Marketing & Communications. Senior Director, HCP Marketing. Finance. Director, Financial

Category: Contact NumberShow more

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos

3 hours ago Accesswire.com Show details

844-916-0895

Contact An Attorney Now: [email protected] 844-916-0895. Allakos (ALLK) Securities Class Action: The complaint alleges Defendants misled investors about the Company's Phase 2 clinical trial (the "ENIGMA Trial") for its flagship AK002 drug intended to …

Category: Contact NumberShow more

Stock Information Allakos

5 hours ago Investor.allakos.com Show details

The Investor Relations website contains information about Allakos's business for stockholders, potential investors, and financial analysts.

Category: Contact NumberShow more

Investor Relations Allakos

7 hours ago Investor.allakos.com Show details

Investor Relations. Allakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. Our initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis

Category: Contact NumberShow more

Allakos Inc. (ALLK) Company Profile & Facts Yahoo Finance

5 hours ago Finance.yahoo.com Show details

See the company profile for Allakos Inc. (ALLK) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

Category: Contact NumberShow more

Events & Presentations Allakos

3 hours ago Investor.allakos.com Show details

Past Events. There are currently no events to display. The presentations on this page contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such

Category: Contact NumberShow more

Allakos Inc Company Profile and News Bloomberg Markets

9 hours ago Bloomberg.com Show details

Company profile page for Allakos Inc including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

Allakos Shareholder Alert: Faruqi & Faruqi, LLP Encourages

5 hours ago Finance.yahoo.com Show details

877-247-4292

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected] CONTACT: FARUQI & FARUQI, LLP 685 Third Avenue

Category: Contact NumberShow more

Allakos Announces AK002 Met All Prespecified Primary and

1 hours ago Investor.allakos.com Show details

1 Treatment responders defined as greater than a 75% reduction in biopsy eosinophil counts and a greater than 30% reduction in TSS 2 TSS is comprised of all 8 patient reported symptoms each measured on a scale from 0 to 10 (abdominal pain, nausea, vomiting, early satiety, loss of appetite, abdominal cramping, bloating, and diarrhea). Safety AK002 was generally well tolerated.

Category: Contact NumberShow more

Allakos Reports Fourth Quarter and Full Year 2020

1 hours ago Finance.yahoo.com Show details

General and administrative expenses were $51.5 million for the full year 2020 as compared to $29.6 million in the same period in 2019, an increase of …

Category: Contact NumberShow more

Insider Trading Transactions at Allakos Inc. (ALLK

1 hours ago Form4oracle.com Show details

Contact Us; Login; Other External Sites Email this page » Number of records: 50. SEC Filing Insider Company Trade Date Transaction Shares Avg. Price Total % Holdings Return; 29-Sep-21 6:51 PM View: James Steven P Director Allakos Inc. (ALLK) 28-Sep-21: Option Exercise : 4,000: $0.52: $2,100.00: 100% 0 to 4.0K: 29-Sep-21 6:51 PM View: James

Category: Contact NumberShow more

Steven P. James Net Worth, Biography & Insider Trading History

3 hours ago Insidertrades.com Show details

(650) 597-5002

The corporate mailing address for Mr. James and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at [email protected]

Category: Contact NumberShow more

ALLAKOS INC. : Shareholders Board Members Managers and

2 hours ago Marketscreener.com Show details

Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in …

Category: Contact NumberShow more

Allakos Reports Third Quarter 2019 Financial Results Allakos

6 hours ago Investor.allakos.com Show details

REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Financial Results. Research and development expenses …

Category: Contact NumberShow more

New Allakos Data Presented at DDW 2021 Suggest that

7 hours ago Finance.yahoo.com Show details

Source: Allakos Inc. CONTACT: Investor Contact: Adam Tomasi, President & COO [email protected]allakos.com Media Contact: Denise Powell [email protected] Su pointed to a number of new semiconductor

Category: Contact NumberShow more

Allakos Inc. Common Stock (ALLK) Institutional Holdings

3 hours ago Nasdaq.com Show details

Allakos Inc. Common Stock (ALLK) including the number of shares held by those institutions in a firm, along with recent purchases and sales …

Category: Contact NumberShow more

Allakos Inc LinkedIn

4 hours ago Linkedin.com Show details

Allakos Inc 2,295 followers on LinkedIn. Allakos Inc. is a publicly traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and

Category: Contact NumberShow more

Allakos Announces Positive Phase 1 Results with Antolimab

3 hours ago Globenewswire.com Show details

The conference ID number is 13700828. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.allakos.com .

Category: Contact NumberShow more

ALLK Allakos Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

Allakos ended the first quarter of 2021 with $615.9 million in cash, cash equivalents and marketable securities. About Allakos. Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases.

Category: Contact NumberShow more

Allakos : Reports First Quarter 2021 Financial Results and

9 hours ago Marketscreener.com Show details

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update REDWOOD CITY, Calif., May 10, 2021 - Allakos Inc. (the 'Company') (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business …

Category: Contact NumberShow more

Results from Prospective Prevalence Study Indicate that

1 hours ago Finance.yahoo.com Show details

The conference ID number is 13712474. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.allakos.com.

Category: Contact NumberShow more

Allakos Announces Positive Phase 2 Results for AK002 in

2 hours ago Globenewswire.com Show details

REDWOOD CITY, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today

Category: Contact NumberShow more

Jobs with Allakos, Inc. BioSpace

4 hours ago Biospace.com Show details

38 articles with Allakos, Inc. Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results. 8/9/2021. Allakos Inc.Allakos Inc.Allakos Inc.Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, provided a business update and reported financial results for the second quarter ended …

Category: Contact NumberShow more

Jeff Macfarland Senior Vice President, Finance Dren

2 hours ago Linkedin.com Show details

Deloitte & Touche. Sep 2009 - Oct 20134 years 2 months. New York, NY - San Diego, CA. · Conducted interim reviews and financial statement audits (including audits of. internal control over

Title: Senior Vice President, Finance at …
Location: San Carlos, California, United States
1. 500+ connections

Category: Contact NumberShow more

Allakos Announces Publication of Results from the Phase 2

2 hours ago Globenewswire.com Show details

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related

Category: Contact NumberShow more

ALLK Stock Price Allakos Inc. Stock Quote (U.S.: Nasdaq

8 hours ago Marketwatch.com Show details

Allakos shares surge 73% in trading debut Jul. 19, 2018 at 1:48 p.m. ET by Ciara Linnane Biotech Allakos prices IPO at $18, above price range

Category: Contact NumberShow more

Allakos Reports First Quarter 2021 Financial Results and

3 hours ago Ca.finance.yahoo.com Show details

Allakos reported a net loss of $55.6 million in the first quarter of 2021 as compared to $27.8 million in the same period in 2020, an increase of $27.8 million. Net loss per basic and diluted share was $1.04 for the first quarter of 2021 compared to $0.57 in the same period in 2020.

Category: Contact NumberShow more

A Study to Assess the Efficacy and Safety of AK002 in

7 hours ago Clinicaltrials.gov Show details

Change in number of symptom-free days per week (patient diary based CSU score) [ Time Frame: From Day 1 to day 29, 85, 155, and 197 ] you or your doctor may contact the study research staff using the contact information provided by the sponsor. Allakos, Inc. More Information.

Category: Contact NumberShow more

Allkex991_6.htm sec.gov

3 hours ago Sec.gov Show details

Allakos ended the third quarter of 2020 with $419.8 million in cash, cash equivalents and marketable securities, which does not include the $271.7 million of net proceeds received from the Company’s follow-on public offering in November 2020.. About Allakos. Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune

Category: Contact NumberShow more

Allakos (NASDAQ:ALLK) Raised to "Hold" at Zacks Investment

Just Now Marketbeat.com Show details

Allakos Inc. is based in CA, United States. "A number of other brokerages have also issued reports on ALLK. Cowen started coverage on Allakos in a research note on Thursday, July 15th. They set an "outperform" rating and a $76.53 price target for the company. Morgan Stanley started coverage on Allakos in a research note on Thursday, August 26th.

Category: Contact NumberShow more

Loss of Endothelial TSPAN12 Promotes Fibrostenotic

8 hours ago Gastrojournal.org Show details

LIMITATIONS: This study is limited by the restricted number of genes within the EoE Diagnostic Panel (EDP) and cross-sectional approach, highlighting the importance of additional replication. IMPACT: Endothelial TSPAN12 contributes to fibrostenotic EoE and is the first molecular correlate of esophageal diameter.

Category: Contact NumberShow more

Allakos Appoints Baird Radford as Chief Financial Officer

9 hours ago Bloomberg.com Show details

Allakos Appoints Baird Radford as Chief Financial Officer REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a …

Category: Contact NumberShow more

Results from Prospective Prevalence Study Indicate that

9 hours ago Bloomberg.com Show details

Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly

Category: Contact NumberShow more

Allkex991_6.htm SEC

3 hours ago Sec.gov Show details

Exhibit 99.1 . Allakos Appoints Baird Radford as Chief Financial Officer . REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer

Category: Contact NumberShow more

Gastritis (Gastrointestinal) Drugs in Development, 2021

9 hours ago Marketresearchreports.com Show details

Market Research Report Summary. Gastritis (Gastrointestinal) - Drugs in Development, 2021 report is published on September 30, 2021 and has 99 pages in it. This market research report provides information about Drug Pipeline, Pharma & Healthcare industry.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Who are allakos inc and what do they do?

REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster pres…

What is the market capitalization of allakos corporation?

The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos's current market capitalization is $4.8 b.

Who are the competitors of allakos oncology?

Competitors of Allakos include ALX Oncology, Vyriad and Sosei Heptares. Where is Allakos headquarters? Allakos headquarters is located at 975 Island Dr #201, Redwood City. Where are Allakos offices? Allakos has an office in Redwood City.

Who is betting on a move in allakos stock?

Are Options Traders Betting on a Big Move in Allakos (ALLK) Stock? Allakos, Inc. engages in the development of therapeutic antibodies.

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Amgen
Att
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes